Abstract:Abstract Background Glaucoma is a leading neurodegenerative disease affecting over 70 million individuals worldwide. Early pathological events of axonal degeneration and retinopathy in response to elevated intraocular pressure (IOP) are limited and not well-defined due to the lack of appropriate animal models that faithfully replicate all the phenotypes of primary open angle glaucoma (POAG), the most common form of glaucoma. Glucocorticoid (GC)-induced ocular hypertension (OHT) and its associated iatrogenic open-angle glaucoma share many features with POAG. Here, we characterized a novel mouse model of GC-induced OHT for glaucomatous neurodegeneration and further explored early pathological events of axonal degeneration in response to elevated IOP. Methods C57BL/6 J mice were periocularly injected with either vehicle or the potent GC, dexamethasone 21-acetate (Dex) once a week for 10 weeks. Glaucoma phenotypes including IOP, outflow facility, structural and functional loss of retinal ganglion cells (RGCs), optic nerve (ON) degeneration, gliosis, and anterograde axonal transport deficits were examined at various stages of OHT. Results Prolonged treatment with Dex leads to glaucoma in mice similar to POAG patients including IOP elevation due to reduced outflow facility and dysfunction of trabecular meshwork, progressive ON degeneration and structural and functional loss of RGCs. Lowering of IOP rescued Dex-induced ON degeneration and RGC loss, suggesting that glaucomatous neurodegeneration is IOP dependent. Also, Dex-induced neurodegeneration was associated with activation of astrocytes, axonal transport deficits, ON demyelination, mitochondrial accumulation and immune cell infiltration in the optic nerve head (ONH) region. Our studies further show that ON degeneration precedes structural and functional loss of RGCs in Dex-treated mice. Axonal damage and transport deficits initiate at the ONH and progress toward the distal end of ON and target regions in the brain (i.e. superior colliculus). Most of anterograde transport was preserved during initial stages of axonal degeneration (30% loss) and complete transport deficits were only observed at the ONH during later stages of severe axonal degeneration (50% loss). Conclusions These findings indicate that ON degeneration and transport deficits at the ONH precede RGC structural and functional loss and provide a new potential therapeutic window for rescuing neuronal loss and restoring health of damaged axons in glaucoma.

Genetic rodent models of glaucoma in representing disease phenotype and insights into the pathogenesis

Using genetic mouse models to gain insight into glaucoma: Past results and future possibilities

The Rodent Model of Glaucoma and Its Implications.

Rodent models of glaucoma and their applicability for drug discovery

Glaucoma Animal Models beyond Chronic IOP Increase

Animal Models of Glaucoma

Angiopoietin-1 Knockout Mice As a Genetic Model of Open-Angle Glaucoma

Molecular pathways in experimental glaucoma models

Exploring the current use of animal models in glaucoma drug discovery: where are we in 2023?

Modeling complex age-related eye disease

Microglial involvement in ocular hypertension

Mouse model of ocular hypertension with retinal ganglion cell degeneration

Gene therapy for glaucoma: Targeting key mechanisms

Practical considerations of genetic rodent models for neurodegenerative diseases.

Insights Into Myopia from Mouse Models

An RNA Sequencing Analysis of Glaucoma Genesis in Mice

Use of rodents as models of human diseases

Assessment of retinal ganglion cell damage in glaucomatous optic neuropathy: Axon transport, injury and soma loss

CNS axonal degeneration and transport deficits at the optic nerve head precede structural and functional loss of retinal ganglion cells in a mouse model of glaucoma

Longitudinal evaluation of morphological, functional and vascular alterations in a rat model of experimental glaucoma

The concept of gene therapy for glaucoma: the dream that has not come true yet